Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy

Fig. 1

Characterization of samples distribution by type of mutation and baseline ctDNA detection and distribution of absolute values for BRAF/NRAS mutant copy number. a Flowchart of total number of patients analyzed for plasma ctDNA indicating the number of patients presenting a BRAF mutation and NRAS mutation, the type of mutations and the number of samples available at baseline (pretreatment). Additionally for the baseline samples the number of samples that showed detectable and undetectable ctDNA level is shown for BRAF mutations as well as for NRAS mutations. b Characterization of BRAF/NRAS mutant copy number distribution for baseline, week 3, 6 and 9 by descriptive statistics (median, range, IQR, mean, std. deviation)

Back to article page